Roche announced the appointment of Dan Malarek as President and CEO of Roche Diagnostics North America, effective August 1, 2026. Malarek currently serves as Chief Executive Officer of Foundation Medicine Inc., an independent affiliate of the Roche Group. Malarek succeeds Brad Moore, who will retire at the end of July after nearly 10 years with Roche. The role will remain based at Roche Diagnostics' North America headquarters in Indianapolis and report to Matt Sause, Global CEO of Roche Diagnostics.
To further strengthen commercial execution across the region, Antonio Vergara has been appointed Chief Commercial Officer of Roche Diagnostics U.S., a newly created role also beginning August 1, 2026. Reporting directly to Malarek, Vergara will lead the commercial organization and its business units.
"We are highly appreciative of Brad for his leadership at Roche, and we wish him the very best in his retirement," said Matt Sause, CEO of Roche Diagnostics.
Sause continued, "Dan is an exceptional leader with the clear vision, experience and track record required to drive our North American commercial operations forward. Together with Antonio's deep commercial expertise and proven leadership, Dan and his team are well positioned to continue to deliver on the strong growth of the North America business and our mission to improve patient care."